A Closer Look: Emerging Medical Therapies for Presbyopia (Archived CE Monograph)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Presbyopia is an age-related impairment in near vision that typically becomes functionally apparent to individuals at or after age 40. Presbyopia can adversely affect the quality of life of the estimated 110 million adults in the United States. Limitations and drawbacks associated with current options available to address presbyopia highlight the need for and interest in new options; topical pharmacologic therapies under investigation for the condition hold promise. This educational activity provides an overview of the age-related loss of accommodative amplitude underlying presbyopia and of emerging topical therapies for improving near-vision function of people with presbyopia. Perspectives on patient selection for the pharmacologic treatments under investigation and potential opportunities for practice growth stemming from this new therapeutic category are also discussed. The desired results of this educational activity are to keep eye care practitioners up to date on potential practice-changing advances in the treatment of presbyopia.
This educational activity is intended for optometrists.
After completing this activity, participants will be better able to:
- Describe the mechanism of accommodation and current theories about its loss and presbyopia development
- Discuss the mechanisms of action of emerging pharmacologic treatments for presbyopia and available clinical data
- Demonstrate selection of potential candidates for pharmacologic presbyopia treatments based on clinical trial data
- Review potential practice-changing strategies associated with pharmacologic presbyopia treatments
|Paul Karpecki, OD, FAAO (Co-Chair)|
University of Pikeville School of Optometry
Director, Cornea and External Disease
Kentucky Eye Institute and Gaddie Eye Centers
|Marguerite B. McDonald, MD, FACS (Co-Chair)|
Clinical Professor of Ophthalmology
New York University Langone Medical Center
New York, New York
Clinical Professor of Ophthalmology
Tulane University Health Sciences Center
New Orleans, Louisiana
Ophthalmic Consultants of Long Island
Oceanside, New York
|Kendall E. Donaldson, MD, MS|
Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute in Plantation
|Adrian Glasser, PhD|
Adrian Glasser Consulting Services, LLC
|Milton M. Hom, OD, FAAO|
Canyon City Eyecare
Priti Batta, MD
Assistant Professor of Ophthalmology
Icahn School of Medicine at Mount Sinai
Director, Medical Student Education
New York Eye and Ear Infirmary of Mount Sinai
New York, New York
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Kendall E. Donaldson, MD, MS, is a consultant for Alcon; Allergan; Dompé US, Inc; Eyevance; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals; Lumenis; Omeros Corporation; Sun Pharmaceutical Industries, Inc; TissueTech, Inc; and Zeiss.
Adrian Glasser, PhD, is a consultant for ViewPoint Therapeutics.
Milton M. Hom, OD, is a consultant for Allergan, Aurinia Pharmaceuticals Inc, Eyenovia, Inc, Eyevance, Laboratoires Théa, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Visus Pharmaceuticals Inc; is on the speakers bureau for Allergan and Bausch & Lomb Incorporated; receives fees for non-CME/CE services from Algernon Pharmaceuticals, Bausch & Lomb Incorporated, and Topcon Medical Systems, Inc; is a contracted researcher for Allergan, Eyenovia, Inc, Hovione, Kala Pharmaceuticals, Nevakar, Inc, Novartis Pharmaceuticals Corporation, Silk Technologies Ltd, Surface Pharmaceuticals Inc, Sydnexis Inc, and Tarsus Pharmaceuticals, Inc.
Paul Karpecki, OD, receives royalties from Bausch & Lomb Incorporated; is a consultant for Aldeyra Therapeutics, Akorn, Inc, Alcon, Allergan, Allysta Pharmaceuticals, Inc, Avellino Labs, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bio-Tissue, DGH Pharma, Inc, Dompé US, Inc, EyeGate, Eyevance, Icare USA, Inc, Imprimis Pharmaceuticals, Inc, Ivantis Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Keplr Vision, Konan Medical USA, Inc, Luneau Technology USA, Inc, MacuLogix, Inc, Mallinckrodt, Novaliq GmbH Germany, Novartis Pharmaceuticals Corporation, OASIS Medical, Ocular Science, Ocular Therapeutix, Inc, OCULUS, Inc, OCuSOFT Inc, Reichert, Inc, Rendia, Inc, RxSIGHT, ScienceBased Health, Sentiss Pharma Pvt Ltd, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, TLC Laser Eye Centers, Vital Tears, and Vmax Vision, Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Mallinckrodt, Novartis Pharmaceuticals Corporation, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Bruno Vision, Dompé US, Inc, Novartis Pharmaceuticals Corporation, and Sight Sciences; and has ownership interest in Bruder Healthcare, EnChroma, Eyedetec Medical, Eyevance, Healthe, Hue.AI, iOR Holdings, Inc, Ivantis Inc, Keplr Vision, LeGrande, Lentechs, Mati Therapeutics, Inc, Ocuphire Pharma, OM Solutions, Omega Ophthalmics, Oyster Point Pharma, Inc, Percept Technologies Inc, PRN, Regener-Eyes, RxSIGHT, Sight Sciences, Silk Technologies Ltd, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearClear, and Visant Medical, Inc.
Marguerite B. McDonald, MD, is a consultant for Akorn, Inc, Alcon, Allergan, Avedro, Inc, Bausch & Lomb Incorporated, Bio-Tissue, BlephEx, Dompé US, Inc, Eyevance, Hellas Ltd, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, NuSight Medical, OCULUS, Inc, OCuSOFT Inc, Omeros Corporation, Orca Surgical, Quidel Corporation, Scope, Sight Sciences, Strōma Medical Corporation, Sun Pharmaceutical Industries, Inc, and TearLab Corporation.
Pritti Batta, MD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 70339-GO (Enduring Distance Learning)
COPE Course Category: General Optometry
Disclosure of Commercial Support
This continuing medical education activity is supported through an unrestricted educational grant from Allergan.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Allergan.
This CE activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 226